Probi signs co-development agreement with leading global food company
Probi has entered into a co-development agreement with a leading global food company focusing on joint clinical development of Probi’s immune health platform ProbiDefendumTM. The objective of the collaboration is to further strengthen the clinical platform of ProbiDefendumTM in preparation of the application for a health claim within the EU that Probi intends to make. A jointly conducted clinical trial on common colds and immune response will commence in Europe in Q1 2012. Probi’s partner has been granted an exclusive global option to negotiate commercial agreements where Probi currently has no commercial products based on the immune health platform.